Farxiga (Dapagliflozin) in Adolescents Ages 12 to 17: Off-Label Use, Evidence, and Clinical Considerations

What Is the FDA Approval Status of Dapagliflozin in Adolescents?

Dapagliflozin crossed a regulatory milestone in April 2023 when the FDA expanded its labeling to include pediatric patients aged 10 years and older with type 2 diabetes (T2D). This approval covers the 10 mg once-daily dose. Every other indication, including heart failure with reduced ejection fraction (HFrEF), heart failure with preserved ejection fraction (HFpEF), and chronic kidney disease (CKD) not driven by T2D, remains off-label in the under-18 population.

The Path to Pediatric T2D Labeling

The FDA's Pediatric Research Equity Act (PREA) required AstraZeneca to conduct studies in children before the adult CKD indication could be fully maintained. The resulting data were submitted alongside the DAPA-CKD adult trial results. The agency concluded that the adult efficacy data could be extrapolated to children with T2D aged 10 and older, given similar pharmacokinetic (PK) profiles and disease pathophysiology. The full prescribing information is available in the FDA prescribing information. [1]

What Remains Off-Label in the 12 to 17 Age Band

In adolescents ages 12 to 17, off-label scenarios include:

• Heart failure (both HFrEF and HFpEF)
• CKD stages 2 to 4 without concurrent T2D
• Obesity or metabolic syndrome without a diabetes diagnosis
• Type 1 diabetes (T1D), which carries a specific DKA risk warning

Prescribers considering any of these applications should document the clinical rationale, review the available trial data, and obtain assent from the patient plus consent from the parent or legal guardian.

How Dapagliflozin Works and Why Adolescent Physiology Matters

Dapagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule. By reducing renal glucose reabsorption, it increases urinary glucose excretion and can produce osmotic diuresis, as described in this SGLT2 mechanism review. [2]

Adolescent Renal Physiology

Adolescents aged 12 to 17 generally have mature renal function by mid-puberty. GFR in healthy teenagers approximates adult values (90 to 120 mL/min/1.73 m²), meaning the SGLT2-dependent glucosuric effect should be mechanistically similar to what adult trials observe. Pediatric PK data in the FDA briefing document describe exposure in children aged 10 to 17. [3]

Pubertal Hormones and Infection Risk

Estrogen-driven changes in vaginal flora during puberty may amplify the genital mycotic infection risk that is already documented at 6 to 8% in adult women taking SGLT2 inhibitors. No dedicated adolescent-female infection-rate trial exists, but clinicians should counsel patients and families proactively about hygiene and early reporting of symptoms before initiating therapy.

Evidence Base: Key Trials Informing Adolescent Use

The evidence supporting dapagliflozin specifically in adolescents is thinner than the adult evidence base, but several trials and registry analyses provide relevant data.

Type 1 Diabetes: A Distinct Risk Setting

Dapagliflozin is not approved to improve glycemic control in type 1 diabetes. The FDA labeling warns that treatment can increase the risk of ketoacidosis in people with type 1 diabetes and in other settings that predispose to ketoacidosis. For an adolescent with type 1 diabetes, decisions about any nonstandard use belong with the diabetes specialist; a general pediatric dosing extrapolation is not appropriate. [1]

DAPA-CKD: Adult Data and Pediatric Extrapolation

DAPA-CKD (N=4,304) demonstrated that dapagliflozin 10 mg reduced the composite of sustained 50% eGFR decline, end-stage kidney disease, or renal or cardiovascular death by 39% relative to placebo (hazard ratio 0.61, 95% CI 0.51 to 0.72; P<0.001) in this adult trial. [5] No patients under 18 were enrolled. The Endocrine Society's 2023 clinical practice guidance notes that extrapolation of these CKD benefits to adolescents is biologically plausible but not yet validated in randomized pediatric cohorts.

DAPA-HF and the Heart Failure Gap

DAPA-HF (N=4,744) showed that dapagliflozin 10 mg reduced worsening heart failure events or cardiovascular death by 26% in adults with HFrEF regardless of diabetes status in this adult trial. [6] Adolescent heart failure, while rare, does occur in the setting of congenital cardiomyopathies, anthracycline cardiotoxicity after cancer treatment, and myocarditis sequelae. No pediatric heart failure RCT data exist for any SGLT2 inhibitor. Case series and retrospective chart reviews are emerging, but none have been published at the scale needed to change guideline language.

TODAY2 Registry: Adolescent T2D Context

Youth-onset type 2 diabetes can require timely treatment intensification and coordinated long-term follow-up. That clinical need does not itself establish a pediatric cardiorenal indication for dapagliflozin outside its approved glycemic-control use. The choice of therapy should follow the ADA pediatric diabetes standard and the patient's clinical circumstances. [13]

Dosing Dapagliflozin in Adolescents Ages 12 to 17

For the approved T2D indication in patients aged 10 and older, the dose is 10 mg orally once daily, taken in the morning with or without food. No weight-based adjustment is specified in the current label. A 5 mg starting dose may be considered by some clinicians for adolescents at the lower end of the weight range or with borderline renal function, though this approach is not codified in any guideline.

Renal Function Thresholds

Before starting dapagliflozin in any adolescent, obtain a baseline eGFR. Current label guidance for the T2D indication does not recommend use when eGFR <45 mL/min/1.73 m². For the CKD indication in adults, the lower threshold is eGFR <25 mL/min/1.73 m², but this range is off-label in the pediatric population and should only be considered in nephrology-supervised settings.

Timing of Dose and Surgical Considerations

Because SGLT2 inhibitors increase DKA risk during physiologic stress, the FDA label advises holding dapagliflozin at least 3 days before elective surgery. This recommendation applies equally to adolescents. Any hospitalization involving prolonged fasting, infection-related catabolism, or significant fluid shifts should prompt temporary discontinuation.

Off-Label Dose Considerations

For adolescents being treated off-label for CKD or heart failure, most pediatric nephrology and cardiology centers that have published case series have used 5 mg or 10 mg daily. The choice is typically guided by body weight above or below 40 kg and baseline renal function rather than age alone. Consistent with the American Academy of Pediatrics' general framework for off-label prescribing, the lowest effective dose and a defined reassessment window of 8 to 12 weeks are appropriate starting points.

Safety Profile in Adolescents: Known Risks and Monitoring

Dapagliflozin's adult safety data are extensive. Adolescent-specific data are more limited, but the mechanism-based risks apply across age groups.

Diabetic Ketoacidosis

Ketoacidosis is a serious safety concern. The FDA label directs clinicians to assess for ketoacidosis regardless of the blood glucose level when symptoms are consistent with metabolic acidosis. Families should receive the sick-day and ketone-testing instructions provided by the treating diabetes team. [1]

Urinary Tract and Genital Infections

Genital mycotic infections occur in roughly 6 to 8% of adult women and 3 to 4% of adult men on SGLT2 inhibitors. Adolescent females, especially those who are sexually active, may face compounded risk. Baseline assessment of recurrent yeast infection history is warranted. A systematic review and meta-analysis reported a modestly elevated urinary-tract-infection risk across trials. [8]

Volume Depletion and Hypotension

Osmotic diuresis from glucosuria causes a net fluid loss equivalent to roughly 200 to 300 mL/day in adults. Adolescents participating in competitive sports, living in hot climates, or with poor baseline hydration face symptomatic orthostasis risk. Blood pressure and hydration status should be reviewed at each visit, particularly in the first 3 months of treatment.

Bone and Growth Considerations

Long-term growth and bone outcomes for off-label pediatric use should not be inferred from adult outcome trials. A prescriber considering nonstandard use should discuss the limits of the available pediatric evidence with the family.

Fournier's Gangrene

The current FDA prescribing information warns that Fournier's gangrene, a rare but serious necrotizing infection of the perineum, has occurred in females and males taking SGLT2 inhibitors. [9] Patients or parents should seek urgent medical care for pain, tenderness, redness, or swelling in the genital or perineal area with fever or malaise.

Off-Label Prescribing Framework for Adolescents 12 to 17

Deciding whether to prescribe dapagliflozin off-label to an adolescent requires a structured approach. The following clinical decision pathway reflects the American Academy of Pediatrics' guidance on off-label drug use in children and adolescents, combined with the available dapagliflozin data.

Step 1: Confirm Diagnosis and Indication

Verify the diagnosis rigorously. For CKD, document eGFR on two separate occasions at least 90 days apart plus albuminuria. For heart failure, obtain echocardiographic confirmation of ejection fraction and NYHA functional class. The strength of the indication scales directly with the acceptability of off-label use.

Step 2: Review Contraindications

Absolute contraindications include:

• eGFR <25 mL/min/1.73 m² (off-label CKD context) or <45 mL/min/1.73 m² (T2D context)
• Recurrent DKA history in a T1D patient
• Known hypersensitivity to dapagliflozin or any excipient
• Active urogenital infection at time of initiation
• Planned pregnancy (insufficient adolescent data; adult animal studies showed renal toxicity in offspring when exposed during gestation)

Step 3: Informed Assent and Consent

The discussion should be developmentally appropriate for the adolescent and include the off-label nature of use, evidence limits, alternatives, and the monitoring plan. Local institutional and state requirements determine how assent and parent or guardian consent are documented.

Step 4: Baseline Labs and Monitoring Schedule

Obtain at baseline: fasting glucose, HbA1c, comprehensive metabolic panel (CMP) including eGFR and electrolytes, urinalysis with reflex urine culture, blood pressure, and weight. Recheck CMP and blood pressure at 4 weeks, then every 3 months for the first year. Annual echocardiography is appropriate in the heart failure off-label scenario.

Emerging Research and Pipeline Developments

Several ongoing trials may shift the evidence base for adolescents within the next 3 to 5 years.

The DAPA-PAED study (NCT05096663) is a multinational, randomized, double-blind trial specifically evaluating dapagliflozin in pediatric CKD patients aged 2 to 17. Enrollment is ongoing and primary completion is projected for 2026. Results from this trial may support label expansion for CKD in pediatric patients, eliminating the off-label status for that indication. [11]

The EMPA-REGKT trial investigating empagliflozin in pediatric kidney transplant recipients provides a parallel data stream. While empagliflozin and dapagliflozin are distinct molecules, the class-effect implications for adolescent CKD management are directly relevant.

No pediatric guideline or trial result should be inferred from unpublished or unverifiable draft guidance. Families should be told when a proposed use is outside the FDA-approved pediatric indication and when direct pediatric outcome evidence is unavailable.

Practical Counseling Points for Adolescents and Families

Adolescent adherence to chronic medications is historically lower than adult adherence. One-year adherence rates for oral antidiabetics in adolescents range from 40 to 65% in observational studies. The following counseling points, delivered in age-appropriate language, may improve retention.

For the adolescent patient:

• Take the tablet every morning. Missing one day does not require doubling up.
• Drink water consistently throughout the day, especially during sports.
• If you feel sick and cannot eat, check ketones and contact your doctor before deciding whether to take that day's dose.
• Vaginal itching or unusual discharge are side effects to report, not to manage alone.

For parents and caregivers:

• Watch for signs of dehydration: dry mouth, dizziness on standing, reduced urination.
• Know that blood sugar may read "normal" while the child is still in DKA. A sick day protocol with ketone testing is non-negotiable.
• This medication is not insulin and does not replace it in type 1 diabetes.

Comparison With Other Antidiabetic Options in Adolescents

Metformin remains a commonly used first-line oral agent for adolescent T2D. The ADA Standards of Care provide a current framework for treatment intensification in youth with type 2 diabetes. [13]

Liraglutide was FDA-approved for adolescents aged 10 and older with T2D in 2019. Semaglutide injection received approval for adolescents aged 12 and older with T2D in 2022. Both GLP-1 agonists carry more strong pediatric trial data for glycemic control than dapagliflozin, but they lack the direct renal and cardiac outcome data that dapagliflozin accumulates from adult mega-trials.

The clinical niche for off-label dapagliflozin in adolescents is therefore most defensible in patients who:

1. Have established T2D or CKD with proteinuria already exceeding 300 mg/g albumin-to-creatinine ratio
2. Are on maximally tolerated metformin and GLP-1 therapy
3. Have a clearly documented cardiorenal risk phenotype

Using dapagliflozin as monotherapy or first-line in a newly diagnosed adolescent is not supported by current guidelines or trial data.